Key result
Introducing a new gatekeeper form to highlight anticoagulant use reduced the projected annual financial loss from on-the-day plastic surgery cancellations from £20,000 to £11,865.
Why the study?
Does a new gatekeeper form highlighting antiplatelet and anticoagulative medications reduce on-the-day surgical cancellations in plastic surgery patients?
Does a new gatekeeper form highlighting antiplatelet and anticoagulative medications reduce on-the-day surgical cancellations in plastic surgery patients?
Implementing a specific gatekeeper form highlighting anticoagulant and antiplatelet medications reduced on-the-day surgical cancellations and associated financial losses in a plastic surgery department.
Answers are grounded in this paper and cite their sources.
May support gatekeeper forms to cut plastic surgery cancellations; leaves open prospective validation in other settings.
It was noted that a number of patients were having their procedures cancelled on the day of surgery because their antiplatelet or anticoagulative medications had not been stopped preoperatively. The team recognised that this problem was leading to an unnecessary waste of the department's labour and financial resources, and more importantly was becoming a source of disappointment and anxiety to patients. A retrospective analysis of all plastic surgery cases was performed for procedures listed for the previous 12 months. All cancellations and the reasons for them were recorded, which came to 23 cases. The sum of the financial tariffs for each cancelled procedure was calculated to assess the financial impact of the identified problem: £20,000. A root cause analysis was performed to assess where this problem was arising in the patient's preoperative journey. The common theme was the lack of information for the gatekeeper regarding the patients' anticoagulant and antiplatelet medications. A new gatekeeper form was introduced to practice with a subsection specifically highlighting antiplatelet and anticoagulative medications. In addition, this issue was highlighted to the relevant staff in the department. After four months, a second PDSA cycle was performed in the same manner. Seven cases were cancelled due to anticoagulants or antiplatelets not being stopped prior to surgery. This equated to a net loss of £11,865 to the department when projected over 12 months, improving on the performance prior to the newly introduced changes.
No takes yet. Share an insight, caveat, or question.
Bass et al. (2014) studied Plastic surgery patients on antiplatelet or anticoagulative medications. New gatekeeper form highlighting antiplatelet and anticoagulative medications vs. Standard practice was evaluated on On-the-day cancellations due to unstopped medications and associated financial loss. Introducing a new gatekeeper form to highlight anticoagulant use reduced the projected annual financial loss from on-the-day plastic surgery cancellations from £20,000 to £11,865.
Synapse has enriched 10 related papers. Consider them for comparative context: